journal
MENU ▼
Read by QxMD icon Read
search

European Journal of Cancer

journal
https://www.readbyqxmd.com/read/28810186/the-efficacy-of-lapatinib-and-capecitabine-in-her-2-positive-breast-cancer-with-brain-metastases-a-systematic-review-and-pooled-analysis
#1
REVIEW
Fausto Petrelli, Michele Ghidini, Veronica Lonati, Gianluca Tomasello, Karen Borgonovo, Mara Ghilardi, Mary Cabiddu, Sandro Barni
INTRODUCTION: Breast cancer (BC) with HER-2/neu overexpression or amplification (HER-2+) is associated with a higher prevalence of brain metastases (BMs) when compared to other subtypes. Among approved drugs for HER-2+ BC, lapatinib (L) is associated with single agent activity toward BMs. We conducted a systematic review to determine the efficacy of L, singly or in combination with capecitabine (C), as a treatment for HER-2+ BMs. MATERIAL AND METHODS: We searched PubMed, EMBASE, The Cochrane Library, SCOPUS, Web of Science, ClinicalTrials...
August 12, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28802709/sex-differences-in-cancer-risk-and-survival-a-swedish-cohort-study
#2
Cecilia Radkiewicz, Anna L V Johansson, Paul W Dickman, Mats Lambe, Gustaf Edgren
AIM: The aim of this study is to firmly delineate temporal and age trends regarding sex discrepancies in cancer risk and survival as well as quantifying the potential gain achieved by eliminating this inequality. METHODS: We performed a population-based cohort study using data on all adult incident cancer cases (n = 872,397) recorded in the Swedish Cancer Register in 1970-2014. To assess the associations between sex and cancer risk and sex and survival, male-to-female incidence rate ratios (IRRs) and excess mortality ratios (EMRs) adjusted for age and year of diagnosis were estimated using Poisson regression...
August 10, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28802189/pt-but-not-pn-stage-of-the-8th-tnm-classification-significantly-improves-prognostication-in-pancreatic-ductal-adenocarcinoma
#3
Anna Melissa Schlitter, Moritz Jesinghaus, Carsten Jäger, Björn Konukiewitz, Alexander Muckenhuber, Ihsan Ekin Demir, Marcus Bahra, Carsten Denkert, Helmut Friess, Günter Kloeppel, Güralp O Ceyhan, Wilko Weichert
The UICC TNM (tumour-node-metastasis) staging system for pancreatic ductal adenocarcinoma (PDAC) has been a matter of debate over decades because survival prediction based on T stages was weak and unreliable. To improve staging, the recently published 8th TNM edition (2016) introduced a conceptually completely changed strictly size-based T staging system and a refined N stage for PDAC. To investigate the clinical value of the novel TNM classification, we compared the prognostic impact of pT and pN stage between the 7th and 8th edition in two well-characterised independent German PDAC cohorts from different decades, including a total number of 523 patients...
August 9, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28802188/risk-of-uterine-cancer-for-brca1-and-brca2-mutation-carriers
#4
Y C Lee, R L Milne, S Lheureux, M Friedlander, S A McLachlan, K L Martin, M Q Bernardini, C Smith, S Picken, S Nesci, J L Hopper, K A Phillips
BACKGROUND: Whether BRCA1 and BRCA2 mutation carriers have a clinically relevant elevated risk of uterine cancer has implications for risk-reducing surgery. AIM: This multicentre, prospective cohort study assessed uterine cancer risk for mutation carriers compared with the general population. METHODS: Eligible mutation carriers were enrolled in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab) cohort study, had a uterus present and no history of uterine cancer at cohort entry...
August 9, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28802187/radiotherapy-access-in-belgium-how-far-are-we-from-evidence-based-utilisation
#5
Y Lievens, H De Schutter, K Stellamans, M Rosskamp, L Van Eycken
INTRODUCTION: Underutilisation of radiotherapy has been observed worldwide. To evaluate the current situation in Belgium, optimal utilisation proportions (OUPs) adopted from the European SocieTy for Radiotherapy and Oncology - Health Economics in Radiation Oncology (ESTRO-HERO) project were compared to actual utilisation proportions (AUPs) and with radiotherapy advised during the multidisciplinary cancer team (MDT) meetings. In addition, the impact of independent variables was analysed...
August 9, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28800492/adding-abiraterone-to-androgen-deprivation-therapy-in-men-with-metastatic-hormone-sensitive-prostate-cancer-a%C3%A2-systematic-review-and-meta-analysis
#6
Larysa H M Rydzewska, Sarah Burdett, Claire L Vale, Noel W Clarke, Karim Fizazi, Thian Kheoh, Malcolm D Mason, Branko Miladinovic, Nicholas D James, Mahesh K B Parmar, Melissa R Spears, Christopher J Sweeney, Matthew R Sydes, NamPhuong Tran, Jayne F Tierney
BACKGROUND: There is a need to synthesise the results of numerous randomised controlled trials evaluating the addition of therapies to androgen deprivation therapy (ADT) for men with metastatic hormone-sensitive prostate cancer (mHSPC). This systematic review aims to assess the effects of adding abiraterone acetate plus prednisone/prednisolone (AAP) to ADT. METHODS: Using our framework for adaptive meta-analysis (FAME), we started the review process before trials had been reported and worked collaboratively with trial investigators to anticipate when eligible trial results would emerge...
August 8, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28800491/survival-for-patients-with-rare-haematologic-malignancies-changes-in-the-early-21st-century
#7
Dianne Pulte, Janick Weberpals, Lina Jansen, Sabine Luttmann, Bernd Holleczek, Alice Nennecke, Meike Ressing, Alexander Katalinic, Hermann Brenner
INTRODUCTION: Population-level survival has improved for common haematologic malignancies in the early 21st century. However, relatively few population-level data are available for rare haematologic malignancies. METHODS: Data were extracted from 12 cancer registries in Germany and the Surveillance, Epidemiology and End Results database in the United States (US). Cases of haematologic malignancies with an incidence of less than 1 per 100,000 were selected for analysis...
August 7, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28797949/a-prediction-model-for-treatment-decisions-in-high-grade-extremity-soft-tissue-sarcomas-personalised-sarcoma-care-persarc
#8
Veroniek M van Praag, Anja J Rueten-Budde, Lee M Jeys, Minna Laitinen, Rob Pollock, Will Aston, Jos A van de Hage, P D Sander Dijkstra, Peter C Ferguson, Anthony M Griffin, Julie J Willeumier, Jay S Wunder, Michiel A J van de Sande, Marta Fiocco
BACKGROUND: To support shared decision-making, we developed the first prediction model for patients with primary soft-tissue sarcomas of the extremities (ESTS) which takes into account treatment modalities, including applied radiotherapy (RT) and achieved surgical margins. The PERsonalised SARcoma Care (PERSARC) model, predicts overall survival (OS) and the probability of local recurrence (LR) at 3, 5 and 10 years. AIM: Development and validation, by internal validation, of the PERSARC prediction model...
August 7, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28787661/understanding-the-role-of-primary-tumour-localisation-in-colorectal-cancer-treatment-and-outcomes
#9
REVIEW
Sebastian Stintzing, Sabine Tejpar, Peter Gibbs, Lars Thiebach, Heinz-Josef Lenz
Metastatic colorectal carcinoma (mCRC) is a heterogeneous disease with differing outcomes and clinical responses and poor prognosis. CRCs can be characterised by their primary tumour location within the colon. The left-sided colon, derived from the hindgut, includes the distal third of the transverse colon, splenic flexure, descending colon, sigmoid colon and rectum. The right-sided colon, derived from the midgut, includes the proximal two-thirds of the transverse colon, ascending colon and caecum. Sometimes, the rectum is described separately, despite originating from the hindgut, and in many clinical series, the left-sided colon includes only tumours within and distal to the splenic flexure...
August 5, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28783542/menopausal-hormone-therapy-and-cancer-risk-an-overestimated-risk
#10
Johanna Simin, Rulla Tamimi, Jesper Lagergren, Hans-Olov Adami, Nele Brusselaers
AIM: We aimed to assess the overall cancer risk among contemporary menopausal hormone therapy (MHT) users in Sweden and the risk for different cancer types. METHODS: A nationwide Swedish population-based cohort study including all 290,186 women aged ≥ 40 years having used systemic MHT during the study period (July 2005 and December 2012), compared with the Swedish female background population. MHT ever-use (all MHT, oestrogen-only MHT [E-MHT] and oestrogen plus progestin MHT [EP-MHT]) was based on the nationwide Prescribed Drug Registry...
August 4, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28783540/survival-of-melanoma-patients-treated-with-targeted-therapy-and-immunotherapy-after-systematic-upfront-control-of-brain-metastases-by-radiosurgery
#11
C Gaudy-Marqueste, A S Dussouil, R Carron, L Troin, N Malissen, A Loundou, S Monestier, S Mallet, M A Richard, J M Régis, J J Grob
BACKGROUND: Targeted therapy (TT) and immunotherapies (ITs) have dramatically improved survival in metastatic melanoma (MM). However, their efficacy on brain metastasis (BM) remains limited and poorly documented. PATIENTS AND METHODS: Retrospective cohort of consecutive MM patients (pts) with BMs, all systematically upfront treated by Gamma-Knife (GK) at first BM and retreated in case of new BMs, from 2010 to 2015 at the time when ipilimumab BRAF ± MEK inhibitors and anti-PD1 were introduced in practice...
August 4, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28783541/increasing-frequency-of-non-smoking-lung-cancer-presentation-of-patients-with-early-disease-to-a-tertiary-institution-in-the-uk
#12
Maria Elena Cufari, Chiara Proli, Paulo De Sousa, Hilgardt Raubenheimer, May Al Sahaf, Hema Chavan, Lynn Shedden, Zakiyah Niwaz, Maria Leung, Andrew G Nicholson, Vladimir Anikin, Emma Beddow, Niall McGonigle, Michael E Dusmet, Simon Jordan, George Ladas, Eric Lim
BACKGROUND: Never-smokers with lung cancer often present late as there are no established aetiological risk factors. The aim of the study is to define the frequency over time and characterise clinical features of never-smokers presenting sufficiently early to determine if it is possible to identify patients at risk. METHODS: We retrospectively analysed data from a prospectively collected database of patients who underwent surgery. The frequency was defined as number of never-smokers versus current and ex-smokers by year...
August 3, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28780480/adjuvant-chemotherapy-in-pt1ab-node-negative-triple-negative-breast-carcinomas-results-of-a-national%C3%A2-multi-institutional-retrospective-study
#13
A de Nonneville, A Gonçalves, C Zemmour, M Cohen, J M Classe, F Reyal, P E Colombo, E Jouve, S Giard, E Barranger, R Sabatier, F Bertucci, J M Boher, G Houvenaeghel
BACKGROUND: Triple-negative breast cancers (TNBCs) are considered as associated with poor outcome, but prognosis of subcentimetric, node-negative disease remains controversial and evidence that adjuvant chemotherapy (CT) is effective in these small tumours remains limited. PATIENTS AND METHODS: Our objective was to investigate the impact of CT on survival in pT1abN0M0 TNBC. Patients were retrospectively identified from a cohort of 22,475 patients who underwent primary surgery in 15 French centres between 1987 and 2013...
August 3, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28780479/q-twist-analysis-of-patients-with-metastatic-castrate-naive-prostate-cancer-treated-by-androgen-deprivation-therapy-with-or-without-docetaxel-in-the-randomised-phase-iii-getug-afu-15-trial
#14
P Marino, P Sfumato, F Joly, K Fizazi, S Oudard, S Culine, M Habibian, J-M Boher, G Gravis
BACKGROUND: Early chemotherapy has recently become a new standard of care for patients with metastatic castrate-naive prostate cancer (mCNPC). The survival benefit is evident in patients with high-volume disease, but less clear in those with low-volume disease. Here, we assessed the trade-offs between toxicity and survival using a Quality-adjusted Time Without Symptoms of disease and Toxicity of treatment (Q-TWiST) analysis. PATIENTS AND METHODS: This analysis was performed from the data of the Genito-Urinary Oncology Group (GETUG)-AFU 15 phase III trial evaluating the benefits of docetaxel (D) combined with androgen deprivation therapy (ADT) versus ADT alone in 385 mCNPC patients...
August 3, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28780466/carboplatin-versus-two-doses-of-cisplatin-in-combination-with-gemcitabine-in-the-treatment-of-advanced-non-small-cell-lung-cancer-results-from-a-british-thoracic-oncology-group-randomised-phase-iii-trial
#15
David Ferry, Lucinda Billingham, Hugh Jarrett, David Dunlop, Penella J Woll, Marianne Nicolson, Riyaz Shah, Joyce Thompson, James Spicer, D Muthukumar, Geraldine Skailes, Pauline Leonard, A D Chetiyawardana, Paula Wells, Conrad Lewanski, Barbara Crosse, Michelle Hill, Piers Gaunt, Kenneth O'Byrne
BACKGROUND: Platinum-based combination chemotherapy is standard treatment for the majority of patients with advanced non-small-cell lung cancer (NSCLC). The trial investigates the importance of the choice of platinum agent and dose of cisplatin in relation to patient outcomes. METHODS: The three-arm randomised phase III trial assigned patients with chemo-naïve stage IIIB/IV NSCLC in a 1:1:1 ratio to receive gemcitabine 1250 mg/m(2) on days 1 and 8 of a 3-week cycle with cisplatin 80 mg/m(2) (GC80) or cisplatin 50 mg/m(2) (GC50) or carboplatin AUC6 (GCb6) for a maximum of four cycles...
August 3, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28779631/diagnostic-characteristics-of-lethal-prostate-cancer
#16
John Thomas Helgstrand, Martin Andreas Røder, Nina Klemann, Birgitte Grønkær Toft, Klaus Brasso, Ben Vainer, Peter Iversen
BACKGROUND: The diagnostic characteristics of men who eventually die from prostate cancer (PCa) and the extent to which early diagnostic strategies have affected these characteristics are unclear. We aimed to investigate trends in survival and clinical presentation at diagnosis in men who eventually died from PCa. PATIENTS AND METHODS: Based on the national database, the Danish Prostate Cancer Registry, a nationwide population-based study of all 19,487 men who died from PCa in Denmark between 1995 and 2013 was conducted...
August 2, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28772128/cytotoxic-tumour-infiltrating-t-lymphocytes-influence-outcome-in-resected-pancreatic-ductal-adenocarcinoma
#17
Philipp Lohneis, Marianne Sinn, Sven Bischoff, Anja Jühling, Uwe Pelzer, Lilianna Wislocka, Marcus Bahra, Bruno V Sinn, Carsten Denkert, Helmut Oettle, Hendrik Bläker, Hanno Riess, Korinna Jöhrens, Jana K Striefler
BACKGROUND: We studied the prognostic effect of CD3-, CD8- and CD103-positive T lymphocytes in a cohort of 165 patients with resected pancreatic ductal adenocarcinomas (PDACs) of the treatment group (adjuvant gemcitabine) and the untreated control group of the CONKO-001 study. METHODS: Immunohistochemical stainings on tissue microarrays (TMAs) against CD3, CD8 and CD103 were performed according to standard procedures. RESULTS: A high number of CD8-positive lymphocytes were significantly and independently associated with longer disease-free survival (DFS) and overall survival (OS) in the overall study population...
July 31, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28772110/leydig-cell-dysfunction-systemic-inflammation-and-metabolic-syndrome-in-long-term-testicular-cancer-survivors
#18
M Bandak, N Jørgensen, A Juul, J Lauritsen, P S Oturai, J Mortensen, P Hojman, J W Helge, G Daugaard
BACKGROUND: Twenty to thirty percent of testicular cancer (TC) survivors have elevated serum levels of luteinising hormone (LH) with or without corresponding low testosterone levels (Leydig cell dysfunction) during clinical follow-up for TC. However, it remains to be clarified if this subgroup of TC survivors has an increased long-term risk of systemic inflammation and metabolic syndrome (MetS) when compared with TC survivors with normal Leydig cell function during follow-up. PATIENTS AND METHODS: TC survivors with Leydig cell dysfunction and a control group of TC survivors with normal Leydig cell function during follow-up were eligible for participation in the study...
July 31, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28768217/randomised-open-label-phase-ii-study-comparing-the-efficacy-and-the-safety-of-cabazitaxel-versus-weekly-paclitaxel-given-as-neoadjuvant-treatment-in-patients-with-operable-triple-negative-or-luminal-b-her2-negative-breast-cancer-genevieve
#19
Sherko Kümmel, Stefan Paepke, Jens Huober, Christian Schem, Michael Untch, Jens Uwe Blohmer, Wolfgang Eiermann, Bernd Gerber, Claus Hanusch, Jörn Hilfrich, Christian Jackisch, Andreas Schneeweiss, Carsten Denkert, Knut Engels, Peter Klare, Peter A Fasching, Gunter von Minckwitz, Nicole Burchardi, Sibylle Loibl
BACKGROUND: The GENEVIEVE study compared the pathological complete response (pCR) rate (ypT0/is ypN0/+) in patients with operable human epidermal growth factor receptor 2 (HER2)-negative breast cancer (BC) treated with either cabazitaxel or paclitaxel. METHODS: GENEVIEVE was a prospective, multicentre, randomised, open-label, phase II study comparing the efficacy and the safety of four 3-weekly cycles cabazitaxel versus 12 weeks of paclitaxel given as neoadjuvant treatment...
July 30, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28764945/corrigendum-to-nuclear-transportation-of-exogenous-epidermal-growth-factor-receptor-and-androgen-receptor-via-extracellular-vesicles-eur-j-cancer-70-2017-62-74
#20
Jolene Read, Alistair Ingram, Hassan A Al Saleh, Khrystyna Platko, Kathleen Gabriel, Anil Kapoor, Jehonathan Pinthus, Fadwa Majeed, Talha Qureshi, Khalid Al-Nedawi
No abstract text is available yet for this article.
July 29, 2017: European Journal of Cancer
journal
journal
30413
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"